These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34503069)

  • 1. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    Perkhofer L; Golan T; Cuyle PJ; Matysiak-Budnik T; Van Laethem JL; Macarulla T; Cauchin E; Kleger A; Beutel AK; Gout J; Stenzinger A; Van Cutsem E; Bellmunt J; Hammel P; O'Reilly EM; Seufferlein T
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
    JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population.
    Hata T; Mizuma M; Motoi F; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Furukawa T; Unno M
    Ann Gastroenterol Surg; 2021 Nov; 5(6):853-864. PubMed ID: 34755017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
    Xie F; Ding D; Lin C; Cunningham D; Wright M; Javed AA; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Le DT; Pishvaian M; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; McPhaul T; Burkhart RA; Burns WR; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Yu J; He J; Wolfgang CL; Zheng L; Liu D; Wu K; Laheru DA
    JCO Precis Oncol; 2022 Jun; 6():e2100404. PubMed ID: 35737913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    Perkhofer L; Gout J; Roger E; Kude de Almeida F; Baptista Simões C; Wiesmüller L; Seufferlein T; Kleger A
    Gut; 2021 Mar; 70(3):606-617. PubMed ID: 32855305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
    J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
    J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
    [No Abstract]   [Full Text] [Related]  

  • 10. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
    JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
    Pishvaian MJ; Blais EM; Brody JR; Rahib L; Lyons E; De Arbeloa P; Hendifar A; Mikhail S; Chung V; Sohal DPS; Leslie S; Mason K; Tibbets L; Madhavan S; Matrisian LM; Petricoin E
    JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
    Pantaleo A; Forte G; Fasano C; Lepore Signorile M; Sanese P; De Marco K; Di Nicola E; Latrofa M; Grossi V; Disciglio V; Simone C
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Cancer:
    Keane F; O'Connor CA; Park W; Seufferlein T; O'Reilly EM
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in pancreatic cancer and potential new therapeutic options.
    Pihlak R; Valle JW; McNamara MG
    Oncotarget; 2017 Sep; 8(42):73240-73257. PubMed ID: 29069866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
    Armstrong SA; Schultz CW; Azimi-Sadjadi A; Brody JR; Pishvaian MJ
    Mol Cancer Ther; 2019 Nov; 18(11):1899-1908. PubMed ID: 31676541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
    Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
    J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.